A health policy model of CKD: 1. Model construction, assumptions, and validation of health consequences.

BACKGROUND A cost-effectiveness model that accurately represents disease progression, outcomes, and associated costs is necessary to evaluate the cost-effectiveness of interventions for chronic kidney disease (CKD). STUDY DESIGN We developed a microsimulation model of the incidence, progression, and treatment of CKD. The model was validated by comparing its predictions with survey and epidemiologic data sources. SETTING & POPULATION US patients. MODEL, PERSPECTIVE, & TIMEFRAME The model follows up disease progression in a cohort of simulated patients aged 30 until age 90 years or death. The model consists of 7 mutually exclusive states representing no CKD, 5 stages of CKD, and death. Progression through the stages is governed by a person's glomerular filtration rate and albuminuria status. Diabetes, hypertension, and other risk factors influence CKD and the development of CKD complications in the model. Costs are evaluated from the health care system perspective. INTERVENTION Usual care, including incidental screening for persons with diabetes or hypertension. OUTCOMES Progression to CKD stages, complications, and mortality. RESULTS The model provides reasonably accurate estimates of CKD prevalence by stage. The model predicts that 47.1% of 30-year-olds will develop CKD during their lifetime, with 1.7%, 6.9%, 27.3%, 6.9%, and 4.4% ending at stages 1-5, respectively. Approximately 11% of persons who reach stage 3 will eventually progress to stage 5. The model also predicts that 3.7% of persons will develop end-stage renal disease compared with an estimate of 3.0% based on current end-stage renal disease lifetime incidence. LIMITATIONS The model synthesizes data from multiple sources rather than a single source and relies on explicit assumptions about progression. The model does not include acute kidney failure. CONCLUSION The model is well validated and can be used to evaluate the cost-effectiveness of CKD interventions. The model also can be updated as better data for CKD progression become available.

[1]  Cigarette smoking among adults--United States, 2004. , 2005, MMWR. Morbidity and mortality weekly report.

[2]  N. Sheerin,et al.  Dialysis or not? A comparative survival study of patients over 75 years with chronic kidney disease stage 5. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  D. Rolla,et al.  Left ventricular hypertrophy in nondiabetic predialysis CKD. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  M. Engelgau,et al.  Changes in incidence of diabetes in U.S. adults, 1997-2003. , 2006, American journal of preventive medicine.

[5]  M. Szklo,et al.  Epidemiology: Beyond the Basics , 1999 .

[6]  R. Sacco,et al.  Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community , 1994, Neurology.

[7]  Desmond E. Williams,et al.  A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  N. Powe,et al.  Screening for proteinuria in US adults: a cost-effectiveness analysis. , 2003, JAMA.

[9]  E. Arias,et al.  United States life tables, 2005. , 2010, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[10]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[11]  Rury R Holman,et al.  Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). , 2003, Kidney international.

[12]  Deeb N Salem,et al.  Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. , 2004, Journal of the American Society of Nephrology : JASN.

[13]  K. Anderson,et al.  Cardiovascular disease risk profiles. , 1991, American heart journal.

[14]  Elizabeth Selvin,et al.  PREVALENCE OFCHRONIC KIDNEY DISEASE IN THE UNITED STATES , 2007 .

[15]  L. Goldman,et al.  The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. , 1997, JAMA.

[16]  V. Jeevanantham,et al.  Referral to Nephrologists for Chronic Kidney Disease Care: Is Non-Diabetic Kidney Disease Ignored? , 2007, Nephron Clinical Practice.

[17]  G. Beck,et al.  Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. , 1997, Kidney international.

[18]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[19]  Charles E. McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[20]  Michael M. Engelgau,et al.  Prevalence of Diabetes and Impaired Fasting Glucose in Adults in the U.S. Population , 2006, Diabetes Care.

[21]  Essam Elsayed,et al.  Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  Amit X Garg,et al.  Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[23]  J. Coresh,et al.  Prevalence of chronic kidney disease in the United States. , 2007, JAMA.

[24]  T. Hostetter,et al.  Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. , 2004, Journal of the American Society of Nephrology : JASN.

[25]  C. Gullion,et al.  Predicting Costs Of Care In Chronic Kidney Disease: The Role Of Comorbid Conditions , 2006 .

[26]  L. Goldman,et al.  Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. , 1987, American journal of public health.

[27]  C. Husten,et al.  Cigarette Smoking Among Adults, United States , 2006 .

[28]  S. Yusuf,et al.  Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. , 2003, Journal of the American Society of Nephrology : JASN.

[29]  R. Foley,et al.  Prevalence of CKD in the United States: a sensitivity analysis using the National Health and Nutrition Examination Survey (NHANES) 1999-2004. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  Kdoqi.  KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  Milton C Weinstein,et al.  Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[32]  G. Cerasola,et al.  Association between biomarkers of inflammation and left ventricular hypertrophy in moderate chronic kidney disease. , 2007, Clinical nephrology.

[33]  C. Husten,et al.  Cigarette smoking among adults--United States, 2006. , 2007, MMWR. Morbidity and mortality weekly report.